ArticleJournal of the Endocrine Society2026
Early Postoperative Predictors of Remission After Transsphenoidal Surgery in Acromegaly: Introduction of the PARS.
Article in Journal of the Endocrine Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Soluble alpha-klotho as an adjunct biomarker of disease activity in acromegaly: Added value beyond GH and IGF-1.Pituitary · 2026Article
- Early Postoperative Predictors of Remission After Transsphenoidal Surgery in Acromegaly: Introduction of the PARS.Journal of the Endocrine Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: Endoscopic endonasal transsphenoidal surgery (EETS) is the standard treatment for acromegaly. However, reliable early markers to predict long-term biochemical remission remain unclear. Objective: This study retrospectively assesses the efficacy of EETS in acromegaly and investigates whether early postoperative hormone levels can independently predict biochemical remission. We also aimed to propose a simple clinical scoring system to facilitate early postoperative decision-making. Methods: We retrospectively analyzed 93 patients with acromegaly who underwent first-time EETS at a single center between 2005 and 2024. Serum growth hormone (GH) was measured on postoperative day (POD) 1, and insulin-like growth factor-1 (IGF-1) was assessed 3 months after surgery, expressed as SD scores. Biochemical remission was defined as nadir GH less than 0.4 ng/mL during oral glucose tolerance testing and age-adjusted IGF-1 within the normal range. Multivariable logistic regression and receiver operating characteristic (ROC) curve analysis were performed to identify and validate independent predictors of remission. Results: Of 93 patients, 79 (84.9%) achieved biochemical remission. Multivariable analysis identified POD1 GH (cutoff: 1.59 ng/mL, AUC: 0.89) and 3-month IGF-1 SD score (cutoff: +1.8, AUC: 0.98) as independent predictors. Based on these factors, we developed a simple risk score-the Postoperative Acromegaly Remission Score (PARS)-which stratifies patients by remission probability. Patients with low PARS values showed remission rates of 100%, whereas those with high scores showed significantly lower remission rates. Conclusion: Early postoperative GH and 3-month IGF-1 SD scores contribute to prognostication of long-term biochemical remission after EETS, and while structural determinants provide strong prognostic effect when early structural certainty is high, PARS may serve as a simple supportive framework when such certainty is insufficient or remains borderline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.